Details for New Drug Application (NDA): 017601
✉ Email this page to a colleague
The generic ingredient in OPTIMINE is azatadine maleate. There are two drug master file entries for this compound. Additional details are available on the azatadine maleate profile page.
Summary for 017601
| Tradename: | OPTIMINE |
| Applicant: | Schering |
| Ingredient: | azatadine maleate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Expired US Patents for NDA 017601
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Schering | OPTIMINE | azatadine maleate | TABLET;ORAL | 017601-001 | Approved Prior to Jan 1, 1982 | ⤷ Start Trial | ⤷ Start Trial |
| Schering | OPTIMINE | azatadine maleate | TABLET;ORAL | 017601-001 | Approved Prior to Jan 1, 1982 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
